Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Lipid composition dictates serum stability of reconstituted high-density lipoproteins: implications for in vivo applications.

Gilmore SF, Carpenter TS, Ingólfsson HI, Peters SKG, Henderson PT, Blanchette CD, Fischer NO.

Nanoscale. 2018 Apr 26;10(16):7420-7430. doi: 10.1039/C7NR09690A.

PMID:
29564446
2.

COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin.

Wang F, Zhang H, Ma AH, Yu W, Zimmermann M, Yang J, Hwang SH, Zhu D, Lin TY, Malfatti M, Turteltaub KW, Henderson PT, Airhart S, Hammock BD, Yuan J, de Vere White RW, Pan CX.

Mol Cancer Ther. 2018 Feb;17(2):474-483. doi: 10.1158/1535-7163.MCT-16-0818. Epub 2017 Dec 28.

PMID:
29284644
3.

The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.

Zeng SX, Zhu Y, Ma AH, Yu W, Zhang H, Lin TY, Shi W, Tepper CG, Henderson PT, Airhart S, Guo JM, Xu CL, deVere White RW, Pan CX.

Clin Cancer Res. 2017 Nov 1;23(21):6580-6591. doi: 10.1158/1078-0432.CCR-17-0033. Epub 2017 Aug 14.

4.

Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model system.

Scharadin TM, He W, Yiannakou Y, Tomilov AA, Saldana M, Cortopassi GA, Carraway KL 3rd, Coleman MA, Henderson PT.

PLoS One. 2017 Jun 6;12(6):e0177761. doi: 10.1371/journal.pone.0177761. eCollection 2017.

5.

A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.

Wang SS, Zimmermann M, Zhang H, Lin TY, Malfatti M, Haack K, Turteltaub KW, Cimino GD, de Vere White R, Pan CX, Henderson PT.

Int J Cancer. 2017 Aug 1;141(3):604-613. doi: 10.1002/ijc.30747. Epub 2017 May 15.

PMID:
28437852
6.

Synthesis of two fluorescent GTPγS molecules and their biological relevance.

Trans DJ, Bai R, Addison JB, Liu R, Hamel E, Coleman MA, Henderson PT.

Nucleosides Nucleotides Nucleic Acids. 2017 Jun 3;36(6):379-391. doi: 10.1080/15257770.2016.1231320. Epub 2017 Mar 10.

7.

DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.

Stornetta A, Zimmermann M, Cimino GD, Henderson PT, Sturla SJ.

Chem Res Toxicol. 2017 Jan 17;30(1):388-409. doi: 10.1021/acs.chemrestox.6b00380. Epub 2017 Jan 3.

8.

Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.

Zimmermann M, Wang SS, Zhang H, Lin TY, Malfatti M, Haack K, Ognibene T, Yang H, Airhart S, Turteltaub KW, Cimino GD, Tepper CG, Drakaki A, Chamie K, de Vere White R, Pan CX, Henderson PT.

Mol Cancer Ther. 2017 Feb;16(2):376-387. doi: 10.1158/1535-7163.MCT-16-0381. Epub 2016 Nov 30.

9.

Diagnostic Microdosing Approach to Study Gemcitabine Resistance.

Scharadin TM, Zhang H, Zimmermann M, Wang S, Malfatti MA, Cimino GD, Turteltaub K, de Vere White R, Pan CX, Henderson PT.

Chem Res Toxicol. 2016 Nov 21;29(11):1843-1848. Epub 2016 Oct 10.

10.

Lipid Cross-Linking of Nanolipoprotein Particles Substantially Enhances Serum Stability and Cellular Uptake.

Gilmore SF, Blanchette CD, Scharadin TM, Hura GL, Rasley A, Corzett M, Pan CX, Fischer NO, Henderson PT.

ACS Appl Mater Interfaces. 2016 Aug 17;8(32):20549-57. doi: 10.1021/acsami.6b04609. Epub 2016 Aug 4.

12.

Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.

Wang S, Zhang H, Scharadin TM, Zimmermann M, Hu B, Pan AW, Vinall R, Lin TY, Cimino G, Chain P, Vuyisich M, Gleasner C, Mcmurry K, Malfatti M, Turteltaub K, de Vere White R, Pan CX, Henderson PT.

PLoS One. 2016 Jan 22;11(1):e0146256. doi: 10.1371/journal.pone.0146256. eCollection 2016.

13.

Paclitaxel Enhances Carboplatin-DNA Adduct Formation and Cytotoxicity.

Jiang S, Pan AW, Lin TY, Zhang H, Malfatti M, Turteltaub K, Henderson PT, Pan CX.

Chem Res Toxicol. 2015 Dec 21;28(12):2250-2. doi: 10.1021/acs.chemrestox.5b00422. Epub 2015 Nov 11.

14.

Cell-free expression of functional receptor tyrosine kinases.

He W, Scharadin TM, Saldana M, Gellner C, Hoang-Phou S, Takanishi C, Hura GL, Tainer JA, Carraway KL 3rd, Henderson PT, Coleman MA.

Sci Rep. 2015 Aug 14;5:12896. doi: 10.1038/srep12896.

15.

Association of Care Practices with Suicide Attempts in US Veterans Prescribed Opioid Medications for Chronic Pain Management.

Im JJ, Shachter RD, Oliva EM, Henderson PT, Paik MC, Trafton JA; PROGRES Team.

J Gen Intern Med. 2015 Jul;30(7):979-91. doi: 10.1007/s11606-015-3220-y. Epub 2015 Feb 19.

16.

Sex differences in chronic pain management practices for patients receiving opioids from the Veterans Health Administration.

Oliva EM, Midboe AM, Lewis ET, Henderson PT, Dalton AL, Im JJ, Seal K, Paik MC, Trafton JA.

Pain Med. 2015 Jan;16(1):112-8. doi: 10.1111/pme.12501. Epub 2014 Jul 13.

PMID:
25039721
17.

Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin.

Zhang H, Li Y, Lin TY, Xiao K, Haddad AS, Henderson PT, Jonas BA, Chen M, Xiao W, Liu R, Lam KS, Pan CX.

Nanomedicine (Lond). 2014;9(12):1807-20. doi: 10.2217/nnm.14.44. Epub 2014 Mar 17.

18.

Controlling the diameter, monodispersity, and solubility of ApoA1 nanolipoprotein particles using telodendrimer chemistry.

He W, Luo J, Bourguet F, Xing L, Yi SK, Gao T, Blanchette C, Henderson PT, Kuhn E, Malfatti M, Murphy WJ, Cheng RH, Lam KS, Coleman MA.

Protein Sci. 2013 Aug;22(8):1078-86. doi: 10.1002/pro.2292. Epub 2013 Jun 27.

19.

Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.

Cimino GD, Pan CX, Henderson PT.

Bioanalysis. 2013 Feb;5(3):369-91. doi: 10.4155/bio.12.325. Review.

20.

Biodistribution and pharmacokinetics of a telodendrimer micellar paclitaxel nanoformulation in a mouse xenograft model of ovarian cancer.

Xiao W, Luo J, Jain T, Riggs JW, Tseng HP, Henderson PT, Cherry SR, Rowland D, Lam KS.

Int J Nanomedicine. 2012;7:1587-97. doi: 10.2147/IJN.S29306. Epub 2012 Mar 27.

21.

Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells.

Zhang H, Luo J, Li Y, Henderson PT, Wang Y, Wachsmann-Hogiu S, Zhao W, Lam KS, Pan CX.

Nanomedicine. 2012 Oct;8(7):1116-24. doi: 10.1016/j.nano.2011.12.004. Epub 2011 Dec 23.

22.

Characterizing diffusion dynamics of a membrane protein associated with nanolipoproteins using fluorescence correlation spectroscopy.

Gao T, Blanchette CD, He W, Bourguet F, Ly S, Katzen F, Kudlicki WA, Henderson PT, Laurence TA, Huser T, Coleman MA.

Protein Sci. 2011 Feb;20(2):437-47. doi: 10.1002/pro.577.

23.

A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance.

Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX.

Int J Cancer. 2011 Sep 15;129(6):1425-34. doi: 10.1002/ijc.25814. Epub 2011 Mar 4.

24.

Human microdosing for the prediction of patient response.

Henderson PT, Pan CX.

Bioanalysis. 2010 Mar;2(3):373-6. doi: 10.4155/bio.10.3. No abstract available.

25.

Salvage of oxidized guanine derivatives in the (2'-deoxy)ribonucleotide pool as source of mutations in DNA.

Henderson PT, Evans MD, Cooke MS.

Mutat Res. 2010 Nov 28;703(1):11-7. doi: 10.1016/j.mrgentox.2010.08.021. Epub 2010 Sep 15. Review.

26.

Towards biomarker-dependent individualized chemotherapy: exploring cell-specific differences in oxaliplatin-DNA adduct distribution using accelerator mass spectrometry.

Hah SS, Henderson PT, Turteltaub KW.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2448-51. doi: 10.1016/j.bmcl.2010.03.020. Epub 2010 Mar 7.

27.

Detection of adriamycin-DNA adducts by accelerator mass spectrometry.

Coldwell K, Cutts SM, Ognibene TJ, Henderson PT, Phillips DR.

Methods Mol Biol. 2010;613:103-18. doi: 10.1007/978-1-60327-418-0_7.

PMID:
19997880
28.

Sources of extracellular, oxidatively-modified DNA lesions: implications for their measurement in urine.

Cooke MS, Henderson PT, Evans MD.

J Clin Biochem Nutr. 2009 Nov;45(3):255-70. doi: 10.3164/jcbn.SR09-41. Epub 2009 Oct 28.

29.

Recent advances in biomedical applications of accelerator mass spectrometry.

Hah SS, Henderson PT, Turteltaub KW.

J Biomed Sci. 2009 Jun 17;16:54. doi: 10.1186/1423-0127-16-54. Review. Erratum in: J Biomed Sci. 2009;16:111. Henderson, Paul T [added]; Turteltaub, Kenneth W [added].

30.

Hydrogen production by a hyperthermophilic membrane-bound hydrogenase in water-soluble nanolipoprotein particles.

Baker SE, Hopkins RC, Blanchette CD, Walsworth VL, Sumbad R, Fischer NO, Kuhn EA, Coleman M, Chromy BA, Létant SE, Hoeprich PD, Adams MW, Henderson PT.

J Am Chem Soc. 2009 Jun 10;131(22):7508-9. doi: 10.1021/ja809251f.

PMID:
19449869
31.

Cell-free expression for nanolipoprotein particles: building a high-throughput membrane protein solubility platform.

Cappuccio JA, Hinz AK, Kuhn EA, Fletcher JE, Arroyo ES, Henderson PT, Blanchette CD, Walsworth VL, Corzett MH, Law RJ, Pesavento JB, Segelke BW, Sulchek TA, Chromy BA, Katzen F, Peterson T, Bench G, Kudlicki W, Hoeprich PD Jr, Coleman MA.

Methods Mol Biol. 2009;498:273-96. doi: 10.1007/978-1-59745-196-3_18.

PMID:
18988032
32.

Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations.

Coldwell KE, Cutts SM, Ognibene TJ, Henderson PT, Phillips DR.

Nucleic Acids Res. 2008 Sep;36(16):e100. doi: 10.1093/nar/gkn439. Epub 2008 Jul 16.

33.

Incorporation of extracellular 8-oxodG into DNA and RNA requires purine nucleoside phosphorylase in MCF-7 cells.

Mundt JM, Hah SS, Sumbad RA, Schramm V, Henderson PT.

Nucleic Acids Res. 2008 Jan;36(1):228-36. Epub 2007 Nov 19.

34.

Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations.

Hah SS, Sumbad RA, de Vere White RW, Turteltaub KW, Henderson PT.

Chem Res Toxicol. 2007 Dec;20(12):1745-51. Epub 2007 Nov 15.

PMID:
18001055
35.

Different apolipoproteins impact nanolipoprotein particle formation.

Chromy BA, Arroyo E, Blanchette CD, Bench G, Benner H, Cappuccio JA, Coleman MA, Henderson PT, Hinz AK, Kuhn EA, Pesavento JB, Segelke BW, Sulchek TA, Tarasow T, Walsworth VL, Hoeprich PD.

J Am Chem Soc. 2007 Nov 21;129(46):14348-54. Epub 2007 Oct 27.

PMID:
17963384
36.

Measurement of 7,8-dihydro-8-oxo-2'-deoxyguanosine metabolism in MCF-7 cells at low concentrations using accelerator mass spectrometry.

Hah SS, Mundt JM, Kim HM, Sumbad RA, Turteltaub KW, Henderson PT.

Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11203-8. Epub 2007 Jun 25.

37.

Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry.

Hah SS, Stivers KM, de Vere White RW, Henderson PT.

Chem Res Toxicol. 2006 May;19(5):622-6.

PMID:
16696564
39.

Urea lesion formation in DNA as a consequence of 7,8-dihydro-8-oxoguanine oxidation and hydrolysis provides a potent source of point mutations.

Henderson PT, Neeley WL, Delaney JC, Gu F, Niles JC, Hah SS, Tannenbaum SR, Essigmann JM.

Chem Res Toxicol. 2005 Jan;18(1):12-8.

PMID:
15651843
40.

In vivo release from a drug delivery MEMS device.

Li Y, Shawgo RS, Tyler B, Henderson PT, Vogel JS, Rosenberg A, Storm PB, Langer R, Brem H, Cima MJ.

J Control Release. 2004 Nov 24;100(2):211-9.

PMID:
15544869
41.

In vivo bypass efficiencies and mutational signatures of the guanine oxidation products 2-aminoimidazolone and 5-guanidino-4-nitroimidazole.

Neeley WL, Delaney JC, Henderson PT, Essigmann JM.

J Biol Chem. 2004 Oct 15;279(42):43568-73. Epub 2004 Aug 6.

42.

Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range.

Sandhu P, Vogel JS, Rose MJ, Ubick EA, Brunner JE, Wallace MA, Adelsberger JK, Baker MP, Henderson PT, Pearson PG, Baillie TA.

Drug Metab Dispos. 2004 Nov;32(11):1254-9. Epub 2004 Jul 30.

44.

The hydantoin lesions formed from oxidation of 7,8-dihydro-8-oxoguanine are potent sources of replication errors in vivo.

Henderson PT, Delaney JC, Muller JG, Neeley WL, Tannenbaum SR, Burrows CJ, Essigmann JM.

Biochemistry. 2003 Aug 12;42(31):9257-62.

PMID:
12899611
45.

High-fidelity in vivo replication of DNA base shape mimics without Watson-Crick hydrogen bonds.

Delaney JC, Henderson PT, Helquist SA, Morales JC, Essigmann JM, Kool ET.

Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4469-73. Epub 2003 Apr 3.

46.

The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma.

Smela ME, Hamm ML, Henderson PT, Harris CM, Harris TM, Essigmann JM.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):6655-60.

47.

Oxidation of 7,8-dihydro-8-oxoguanine affords lesions that are potent sources of replication errors in vivo.

Henderson PT, Delaney JC, Gu F, Tannenbaum SR, Essigmann JM.

Biochemistry. 2002 Jan 22;41(3):914-21.

PMID:
11790114
48.

Human endonuclease III acts preferentially on DNA damage opposite guanine residues in DNA.

Eide L, Luna L, Gustad EC, Henderson PT, Essigmann JM, Demple B, Seeberg E.

Biochemistry. 2001 Jun 5;40(22):6653-9.

PMID:
11380260
49.

Selective photocleavage of DNA and RNA by anthraquinone derivatives: targeting the single-strand region of hairpin structures.

Fernandez-Saiz M, Henderson PT, Wilson WD, Schuster GB.

Photochem Photobiol. 1999 Dec;70(6):847-52.

PMID:
10628298
50.

Long-distance charge transport in duplex DNA: the phonon-assisted polaron-like hopping mechanism.

Henderson PT, Jones D, Hampikian G, Kan Y, Schuster GB.

Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8353-8.

Supplemental Content

Loading ...
Support Center